Goldman Sachs' Ankang Li heads to biotech Terns as new CFO; SV recruits new partner for Dementia Discovery Fund
→ Fresh off a NASH deal with French drugmaker Genfit, Terns Pharma has appointed Ankang Li as CFO. The Chinese biotech scooped Li from Goldman Sachs, where he led high profile biotech IPOs as executive director of healthcare investment banking. A law school graduate with a background in biomedical research — his career has taken him to Salk Institute and Merck’s Asia Pacific innovation hub — Li will hold extensive responsibilities in corporate financing and business development.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.